

(19) United States

(12) **Patent Application Publication** (10) Pub. No.: US 2006/0166312 A1 Mitani et al. $\frac{12}{12}$ Jul. 27, 2006

- (54) NOVEL MICROORGNAISM SENSITIVE TO (30) Foreign Application Priority Data LYSOZYME
- (75) Inventors: Yasuo Mitani, Hokkaido (JP): Nobutaka Nakashima, Hokkaido (JP); Publication Classification Tomohiro Tamura, Hokkaido (JP) (51)

Correspondence Address: FOLEY AND LARDNER LLP
SUITE 500

- WASHINGTON, DC 20007 (US) (57) ABSTRACT

(73) Assignee: National Institute of Advanced Indus-
-
-
- (86) PCT No.: PCT/UP03/10342

Aug. 20, 2002 (JP)...................................... 2002-239554

3OOOK STREET NW (52) U.S. Cl. 435/69.1; 435/252.3: 530/350

(13) Fractional Historical Science and Technology, Chiyoda-

Representing to A microorganism of the genus *Rhodococcus* is provided

which has a higher sensitivity to lysozyme at a low concen-

Ru, Tokyo (JP) which has a higher sensitivity to lysozyme at a low concentration than a wild-type strain, which can easily cause cell lysis, and from which a recombinant protein expressed (21) Appl. No.: 10/524,630 lysis, and from which a recombinant protein expressed therein is easily recovered. More specifically, a mutant (22) PCT Filed: Aug. 14, 2003 microorganism of the genus Rhodococcus having a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus.

 10^{\degree} 10^{\degree} 10^{\degree} 10^{\degree} 10

Fig. 2

Rhodococcus erythropolis L-65

Fig. 3

Rhodococcus erythropolis L-88

Fig. 4

Rhodococcus erythropolis JCM3201

Patent Application Publication Jul. 27, 2006 Sheet 5 of 5

US 2006/0166312 A1

NOVEL, MICROORGNAISM SENSITIVE TO LYSOZYME

TECHNICAL FIELD

[0001] The present invention relates to a microorganism of the genus Rhodococcus suitable for production of a recombinant protein, and more specifically, to a mutant strain more sensitive to lysozyme at a low concentration than a wild type strain and capable of easily causing cell lysis. Use of the mutant strain makes it easier to extract and recover an expressed protein.

BACKGROUND ART

[0002] As a technique for expressing a recombinant protein in a microbial host, an expression system using *Escheri*chia coli (E. coli) as a host has been generally and widely used. This is because $E.$ coli is extremely easy to handle in a laboratory. More specifically, E. coli is confirmed as a safe microbial host and proliferates at a high rate, and its molecu lar biological operations in a laboratory are well established. On the other hand, development of host microorganisms having usefulness and advantages over E. coli in view of recombinant protein expression has progressed.

[0003] Microorganisms of the genus Rhodococcus are not pathogenic, except a few, and easily cultured in an ordinary laboratory. In addition to such essential conditions, they have the function as microbial catalysts, which is considered to be extremely useful from an industrial point of view. For these reasons, recently, various molecular biological tech niques have been developed by use of such microorganisms. For example, in an attempt to add a further useful function to the microorganisms, techniques involving gene recombi nation has been developed. As a result, a shuttle vector was established which can replicate autonomously both in E. coli and in a microorganism of the genus Rhodococcus (R, De Motet al., Microbiology 143, 3137-3147, (1997)). Further more, there is a report that a transposable transposon is present in a microorganism of the genus Rhodococcus (I, Nagy et al., J. Bacteriol. 179,4635-4638 (1997)). Thus, it is expected to improve the microorganism in function, for example, by destroying the gene or integrating an exogenous gene into the chromosome.

 $[0004]$ In an attempt to further improve a microbial catalytic action based on such a molecular biological establishment, development of a vector for expressing a recombinant protein has been underway (JP Patent Publication (Kokai) No. 10-248578 A (1998)).

[0005] A microorganism of the genus Rhodococcus, namely, Rhodococcus erythropolis is not only useful as a microbial catalyst but also advantageous in that it can grow under a low temperature condition of 4° C. For this reason, it is expected that Rhodococcus erythropolis may produce a recombinant protein or the like in a temperature range where E. coli could not be used. Development of an inducible expression vector has been underway for such a purpose (the application already filed by Tamura, on Aug. 12, (2002)).

[0006] However, the cell wall of a microorganism of the genus Rhodococcus is particular and rigid in structure com pared to those of other gram-positive bacteria. Therefore, extraction of a cellular content from the microorganism is complicated and difficult compared to the case of E. coli.

More specifically, a microorganism of the genus Rhodococcus has an extremely strong resistance to a cell-wall lytic enzyme used generally for microbial cell lysis, such as lysozyme. Examples of a cell lysis method include a method of exposing cell wall to a high-concentration antibiotic, Such as penicillin, for a predetermined time to weaken the cell wall and then being subjected to cell lysis with lysozyme, and a method of applying ultrasonic treatment to bacterial cells for a long time to physically destroy them. However, these methods are complicated in process, it is difficult to treat a large amount of cells, and specimens are not likely to be treated uniformly. These problems are significant in view of industrial use. The effectiveness of an antibiotic such as penicillin is brought by inhibiting a de-novo synthesis of a cell wall and therefore the cell wall completed in synthesis is not affected by such an antibiotic. Therefore, the effect of such an antibiotic is considered to be low in low-temperature conditions where rapid growth is not expected.

 $[0007]$ It is known that the cell wall structure of a microorganism of the genus Rhodococcus is commonly seen in bacteria of the genus Corynebacterium (C. E. Barry III et al., Prog. Lipid Res. 37, 143-179 (1988)) and an invention similar to the present invention has been made in view of an object of facilitating a molecular biological operation such as transformation (JP Patent Publication (Kokoku) No. 01-003475 B (1989), T. Hirasawa et al., J. Bacteriol. 182, 2696-2701 (2000)).

DISCLOSURE OF THE INVENTION

[0008] The present invention is directed to providing a microorganism of the genus Rhodococcus improved in sensitivity to lysozyme and capable of being lysed with lysozyme at a low concentration, the microorganism allow ism with lysozyme after an exogenous gene is integrated to the microorganism and allowed to express. Furthermore, the present invention provides a method of producing an exog enous protein by use of the microorganism of the genus Rhodococcus having a high sensitivity to lysozyme.

[0009] The present inventors conducted studies with a view toward to attain an expression system for a recombi nant protein by use of a microorganism of the genus Rhodococcus by overcoming a difficulty in extracting a cellular content. As a result, they found a novel microorganism of the genus Rhodococcus more sensitive to lysozyme at an extremely low concentration than a wild type strain. More specifically, mutation was induced in a wild type strain to obtain a mutant that cannot grow in a medium containing lysozyme. Mutation is usually induced by a chemical mutagen such as nitrosoguanidine or irradiation with radioactive rays. However, taking safety and convenience into consideration, ultraviolet ray irradiation is employed in the present invention. Furthermore, the present inventors found that cell lysis can be performed only by lysozyme treatment without pretreatment with penicillin or the like, and that a cellular content such as a recombinant protein accumulated in the cells can be extracted in a much easier manner than a conventional method. Based on these findings, the present invention was completed.

[0010] More specifically, the present invention includes

0011 (1) A mutant of a microorganism of the genus Rhodococcus having a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus.

[0012] (2) The microorganism of the genus $Rhodococcus$ according to item (1), in which the microorganism of the genus Rhodococcus is Rhodococcus erythropolis.

[0013] (3) The microorganism of the genus *Rhodococcus* according to item (2) , in which the *Rhodococcus ervthro*polis is Rhodococcus erythropolis strain L-65 (deposited on Jun. 12, 2002, originally at the International Patent Organ ism Depositary of the National Institute of Advanced Indus trial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan) under Accession No. FERM BP-8443) or Rhodococcus erythropolis strain L-88 (deposited on Jun. 12, 2002, originally at the International Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (Tsukuba Cen tral 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan, Accession No. FERM BP-8444).

 $[0014]$ (4) A method of producing a protein comprising

[0015] transforming a mutant of a microorganism of the genus Rhodococcus having a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus by a gene encoding an exogenous protein; expressing the gene; and treating the microorganism of the genus Rhodococcus with lysozyme, thereby extracting and recovering the protein.

 $\lceil 0016 \rceil$ (5) The method of producing a protein according to item (4), in which the microorganism of the genus Rhodococcus is Rhodococcus erythropolis.

 $\lceil 0017 \rceil$ (6) The method of producing a protein according to item (5), in which the Rhodococcus erythropolis is Rhodococcus erythropolis strain L-65 (Accession No. FERM BP-8443) or Rhodococcus erythropolis strain L-88 (Acces sion No. FERM BP-8444).

[0018] Now, the present invention will be explained in detail.

[0019] A microorganism of the genus Rhodococcus according to the present invention is a mutant microorgan ism of the genus Rhodococcus, which has a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus. The microorganism of the genus Rhodococcus is not limited to a specific species and includes Rhodococcus erythropolis, Rhodococcus fascians, and Rhodococcus opacus. The wild-type microorganism of the genus Rhodococcus refers to a microorganism belonging to the genus Rhodococcus and having no genetic mutation, for example, Rhodococcus erythropolis strain JCM 3201. More specifically, the microorganism of the genus Rhodococcus according to the present invention having a higher sensitivity to lysozyme is a mutant derived from a wild-type microorganism of the genus Rhodococcus as a parent strain, and having an increased sensitivity to lysozyme compared to the parent Strain. The phrase "having an increased sensitivity to lysozyme" means that cell lysis may occur at a low lysozyme concentration. If cell growth is inhibited when lysozyme is added to a medium where a microorganism is cultured, it is said that the microorganism has a sensitivity to lysozyme. The sensitivity to lysozyme can be expressed by a minimum lysozyme concentration capable of inhibiting the growth of a microorganism (a minimum growth inhibitory lysozyme concentration). A source providing lysozyme is not limited, for example, egg-white lysozyme may be used. The minimum growth inhibitory lysozyme concentration is obtained as follows: for example, a microorganism of the genus Rhodococcus is prepared in a liquid medium at a density of 1×10 to 1×10^5 cells/10 µl. Lysozyme is serially diluted from a concentration of several hundreds ug/ml to several μ g/ml. Each of the serial dilutions is added to 10 μ l of the liquid medium prepared above. The microorganism is cultured for several days. The lysozyme concentration that inhibits the growth of a microorganism of the genus Rhodococcus represents the minimum growth inhibitory lysozyme concentration. Alternatively, the degree of sensitivity to lysozyme can be determined by adding lysozyme to a predetermined concentration of a microorganism of the genus Rhodococcus, and monitoring a change in absorbence while culturing. In this case, a strain non-sensitive to lysozyme continues to grow without causing cell lysis by lysozyme, and thus absorbence increases with time, whereas a strain sensitive to lysozyme causes cell lysis by lysozyme, and absorbence decreases rapidly.

 $[0020]$ The minimum growth inhibitory lysozyme concentration of a microorganism of the genus Rhodococcus having a high sensitivity to lysozyme according to the present invention is preferably 50 µg/ml or less, more preferably, 25 μ g/ml or less, and most preferably 13 μ g/ml or less. This is equal to or less than $\frac{1}{8}$, preferably $\frac{1}{16}$, and particularly preferably, $\frac{1}{30}$ of the minimum growth inhibitory lysozyme concentration of a wild type, that is, a parent strain.

[0021] A microorganism of the genus Rhodococcus generally has a high resistance to lysozyme, so that the micro organism cannot be lysed with lysozyme alone. Therefore, an antibiotic Such as penicillin must be used at a high concentration to inhibit the cell wall synthesis of the micro organism during growth to weaken the cell wall, and then lysozyme is applied to the microorganism. However, the organism of the genus Rhodococcus according to the present invention can be lysed with lysozyme alone.

[0022] The organism of the genus $Rhodococcus$ having a high sensitivity to lysozyme according to the present inven tion can be obtained by treating a wild-type microorganism of the genus Rhodococcus such as Rhodococcus erythropolis strain JCM 3201 with a chemical mutagen or a physical mutagen, culturing it in an agar medium, transferring the colonies thus grown onto a medium containing lysozyme and a medium not containing lysozyme, culturing both, and selecting a bacterial cell not grown in the medium contain ing lysozyme. The sensitivity to lysozyme can be deter mined by the aforementioned sensitivity test. Examples of such chemical mutagens include alkylation agents such as N-methyl-N'-nitro-N-nitrosoguanidine and mustard gas, non-alkylation agents such as hydradine and nitrite, DNA nucleotide analogs such as 5-bromo uracil, 2-aminopterin, and DNA intercalators, such as acrydine orange. Examples of Such physical mutagens include ultraviolet rays, X-rays, Y-rays, and neutron beam. A method of treating a microor ganism with a mutagen, the concentration of a chemical mutagen to be used, and the intensity of a physical mutagen to be used may be appropriately selected in accordance with a known method.

[0023] Examples of such an microorganism of the genus Rhodococcus having a high sensitivity to lysozyme accord ing to the present invention include Rhodococcus erythropolis strain L-65 (Accession No. FERM BP-8443) and Rhodococcus erythropolis strain L-88 (Accession No. FERM BP-8444).

 $[0024]$ In a microorganism of the genus *Rhodococcus* having a high sensitivity to lysozyme according to the present invention, its sensitivity to lysozyme is higher than that of a wild-type strain, that is, a parent stain; however, the sensitivity to at least one member of antibiotics such as ampicillin, kanamycin, chloramphenicol, tetracycline, and thiostreptone is equal to that of the wild strain and thus has no significant difference. Even if the sensitivity differs between them, the difference from the wild type is not so large as that from lysozyme sensitivity. More specifically, a microorganism of the genus *Rhodococcus* having a high sensitivity to the lysozyme according to the present invention has a resistant gene to a certain antibiotic integrated as a selection marker. Therefore, when the microorganism of the present invention is transformed by an expression vector having an exogenous gene integrated therein and a trans formant is selected based on the selection marker, non transformed microorganism of the genus Rhodococcus cannot grow since the sensitivity to the antibiotic is not lowered and thus only transformant can be selected. In this respect, as long as a microorganism of the genus Rhodococcus having a high sensitivity to lysozyme according to the present invention has a sensitivity to the antibiotic to be used for selection even if the sensitivity to other antibiotics is low, it can be used.

[0025] A recombinant protein can be efficiently obtained by using a microorganism of the genus Rhodococcus having a high sensitivity to lysozyme according to the present invention. To explain more specifically, the protein can be obtained by transforming a microorganism of the genus Rhodococcus having a high sensitivity to lysozyme accord ing to the present invention with a gene encoding an exogenous protein derived from other species, culturing the transformed Rhodococcus microorganism in the conditions where the gene can be expressed, thereby expressing the exogenous protein, treating the microorganism having the expressed protein therein with lysozyme, thereby extracting the protein, and purifying and recovering the protein from the extract solution. The transformation of a microorganism of the genus Rhodococcus of the present invention may be performed in accordance with a known method. At this time, a transformation efficiency of a microorganism of the genus Rhodococcus with a reduced sensitivity to lysozyme is equivalent to that of a wild type strain, that is, a parent strain, even if there is a difference between them, the difference is not so significant. In some cases, the transformation effi ciency is more or less lowered by the effect of introduction
of mutation; however, there is no case where the efficiency of expressing and producing an exogenous protein is significantly reduced.

[0026] Transformation can be performed by using a known expression vector for a microorganism of the genus Rhodococcus or by expression vector pHN170 constructed by the present inventors such that the expression of the vector can be induced by thiostreptone.

[0027] A microorganism of the genus Rhodococcus transformed by integrating an exogenous gene therein is cultured. After the exogenous gene is expressed, the cells of the microorganism are collected by centrifugation, or the like, suspended in a buffer solution, such as a phosphate buffer, having lysozyme dissolved therein, and incubated at a temperature near an optimal temperature of lysozyme for several tens to several hours. The cells of the microorganism are lysed by the action of lysozyme and the expressed protein is extracted into the buffer solution. The extracted protein is purified by a known protein purification method to obtain the protein. The concentration of lysozyme to be used in cell lysis is 0.1 mg/ml to 10 mg/ml, preferably about 1 mg/ml. Purification can be performed by use of any sepa ration and purification method. For example, ammonium sulfate precipitation, gel filtration, ion exchange chromatography, and affinity chromatography may be used singly or in an appropriate combination. In the case where an expression product is present in the form of a fusion protein with GST. His tag, it may be purified by use of the nature of a peptide or a protein that is fused to a desired protein. To explain more specifically, since GST has an affinity for glutathione, the desired protein can be efficiently purified by affinity chromatography by use of a column having a carrier to which glutathione is attached.

[0028] The specification includes the specification and/or contents of the drawings of JP Patent Application No. 2002-239554 based on which the present application claims the priority.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIG. 1 shows photographs of LB agar mediums onto which serially diluted culture solutions are spotted for comparing their growth;

 $[0030]$ FIG. 2 is a graph showing a growth curve of Rhodococcus erythropolis strain L-65;

[0031] FIG. 3 is a graph showing a growth curve of Rhodococcus erythropolis strain L-88;

[0032] FIG. 4 is a graph showing a growth curve of Rhodococcus erythropolis strain JCM 3201; and

[0033] FIG. 5 shows SDS polyacrylamide electrophoresis of the cases where a PIP protein was expressed by Rhodococcus erythropolis strain L-65, L-88 and JCM3201.

BEST MODE FOR CARRYING OUT THE INVENTION

[0034] The present invention will be now explained with reference to Examples, which should not be construed as limiting the present invention.

EXAMPLE 1

0035) Production of Lysozyme-Sensitive Bacterial Strain

[0036] Rhodococcus erythropolis strain JCM 3201 was cultured in LB medium (1% Difco Bacto Tryptone, 0.5% Difco Yeast Extract, and 1% sodium chloride) with shaking at 30° C. The LB medium was taken in the middle of the logarithmic growth period and appropriately diluted. The dilution was applied onto an LB medium plate containing 1.5% agar at a density of about 5×10^3 bacterial cells per plate, and the application surface was irradiated with 254 nm ultraviolet ray by means of an ultraviolet-ray irradiation apparatus (manufactured by Atto, power: 4W) placed at a distance of 15 cm from the application surface for 20 seconds. The medium irradiated with the ultraviolet ray was cultured stand still at 30 $^{\circ}$ C. for 2 days to obtain about 5×10^{2} colonies per plate. The colonies were scraped by a cocktail stick and inoculated onto a 96-well plate filled with about 150 ul of LB medium. After the colonies were sufficiently

Jul. 27, 2006

suspended, a part of the suspension was inoculated onto a 96-well plate filled with 150 ul of LB medium containing lysozyme derived from egg-white in a concentration of 50 ug/ml (manufactured by Sigma, hereinafter simply referred to as "lysozyme'). The couple of plates thus obtained were cultured stand still at 30°C. for 2 days. As a result, a mutant strain capable of growing only in lysozyme-free LB medium was obtained as a lysozyme sensitive strain. Examples of such a novel lysozyme sensitive microorganism according to the present invention include Rhodococcus erythropolis strain L-65 and Rhodococcus erythropolis strain L-88, which was originally deposited on Jun. 12, 2002 under Accession Nos. FERM BP-8443 and FERM BP-8444, respectively at the International Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology (Tsukuba Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan). A request for transferring the microorgan isms from the original deposition to the international depo sition based on the Budapest Treaty was made and accepted as of Jul. 28, 2003. The bacterial strain was inoculated in LB medium and cultured with shaking at 30° C. A part of the culture solution was taken in the middle of the logarithmic growth period and diluted with fresh LB medium so as to contain 1×10^5 , 1×10^4 , 1×10^3 , 1×10^2 , and 1×10 cells in 10 µl of the LB medium. The diluted culture solutions thus prepared were spotted onto each of LB agar mediums containing lysozyme in concentrations of 50, 25, 12.5 and 6.3 ug/ml. After the mediums were cultured at 30° C. for 2 days, the presence or absence of bacterial cells grown on mediums was checked. In this manner, the minimum growth inhibition concentration was determined (Table 1 and FIG. 1). As shown in the figure, the culture solutions of bacterial strains JCM3201, L-65, and L-88 were dropped onto an LB agar medium containing no lysozyme and an LB agar medium containing lysozyme (12.5 µg/ml) and then subjected to culturing. The bacterial strains JCM3201, L-65, and L-88 cells were dropped respectively onto the upper stage, the middle stage, and the lower stage of the LB agar medium and cultured as shown in FIG. 1. The numbers of bacterial cells contained in culture solutions were 1×10^5 , 1×10^4 , 1×10^3 , 1×10^2 , and 1×10 cells in this order from the left.

TABLE 1.

Bacterial strain	Deposition No.	Minimum growth- inhibiting lysozyme concentration (ug/ml)
Rhodococcus erythropolis strain L-65	FERM BP-8443	12.5
Rhodococcus erythropolis strain L-88	FERM BP-8444	12.5
Rhodococcus erythropolis strain JCM 3201	ATCC25544	>400

EXAMPLE 2

[0037] Turbidity change of Rhodococcus erythropolis strain L-65 culture solution by addition of lysozyme

[0038] To 100 ml of LB medium, *Rhodococcus erythro-*
polis strain L-65 was inoculated and cultured with shaking at 30° C. The absorbence OD_{600} of the culture solution was measured at an absorption wavelength of 600 nm every hour from the beginning of the logarithmic growth period. When $OD₆₀₀$ reached about 0.2, the volume of the culture solution was divided into halves. To one of them, lysozyme was added to a final concentration of 12.5 μ g/ml. No lysozyme was added to the other. While both solutions were further cultured continuously, the absorbence was measured. The results are shown in **FIG. 2**. The growth profiles of *Rhodo*coccus erythropolis strain L-65 culture solutions with Lysozyme (12.5 μ g/ml) and without lysozyme were shown by absorbence at 600 nm. When $OD₆₀₀$ reached about 0.2, lysozyme was added (Indicated by the arrow in the figure). When lysozyme was added, a sharp decrease in absorbence was observed. This is considered because bacterial cell lysis was caused by lysozyme.

EXAMPLE 3

[0039] Turbidity change of Rhodococcus erythropolis strain L-88 culture solution by addition of lysozyme

[0040] The same operation as in Example 2 was performed by use of Rhodococcus erythropolis strain L-88. Absorbence was measured and the results are shown in FIG. 3. The growth profiles of culture solutions of Rhodococcus erythropolis strain L-88 with lysozyme (12.5 ug/ml) and without lysozyme were shown by absorbence at 600 nm. When $OD₆₀₀$ reached about 0.2, lysozyme was added (Indicated by the arrow in the figure). When lysozyme was added, a sharp decrease in absorbence was observed. This is con sidered because bacterial cell lysis was caused by lysozyme.

COMPARATIVE EXAMPLE 1.

[0041] Turbidity change of Rhodococcus erythropolis strain JCM 3201 culture solution by addition of lysozyme

 $[0042]$ The same operation as in Example 2 was performed by use of Rhodococcus erythropolis strain JCM 3.201. Absorbence was measured and the results are shown in FIG. 4. The growth profiles of culture solutions of Rhodococcus erythropolis strain JCM 3201 with lysozyme (12.5 μ g/ml) and without lysozyme were shown by absorbence at 600 nm. When OD_{600} reached about 0.2, lysozyme was added (Indicated by the arrow in the figure). Regardless of the presence or absence of lysozyme, the same tendency of growth was observed.

EXAMPLE 4

[0043] Sensitivity of lysozyme sensitive bacterial strain to ampicillin

[0044] The sensitivity of *Rhodococcus erythropolis* strain L-65 and L-88 to ampicillin was determined in the same manner as in Example 1. To explain more specifically, the bacterial cells of each strain were inoculated in LB medium and cultured with shaking at 30° C. A part of the culture solution was taken in the middle of logarithmic growth period and diluted with fresh LB medium so as to contain 1×10^5 , 1×10^4 , 1×10^3 , 1×10^2 , and 1×10 cells in 10 µl of the LB medium. The diluted culture solutions thus prepared were dropped onto each of LB agar mediums containing lysozyme in concentrations of 15, 10, 1, and 0.1 ug/ml. After the mediums were cultured at 30° C. for 2 days and the presence or absence of bacterial cells grown on the mediums was checked. In this manner, the minimum growth inhibition concentration was determined (Table 2). Similarly, the wild type and the mutant strain were compared for sensitivity to

TABLE 2

Bacterial strain	Deposition No.	Minimum growth- inhibiting ampicillin concentration (ug/ml)
Rhodococcus erythropolis strain L-65	FERM BP-8443	
Rhodococcus ervthropolis strain L-88	FERM BP-8444	
Rhodococcus erythropolis strain JCM 3201	ATCC25544	15

EXAMPLE 5

[0045] Transformation efficiency of lysozyme sensitive strain

[0046] The transformation of Rhodococcus erythropolis was performed by an electroporation method. The method will be described in detail below. Rhodococcus erythropolis strain JCM 3201, L-65, and L-88 were cultured in 100 ml of LB medium with shaking at 30° C. until they reach their logarithmic growth periods. The culture solutions were cooled on ice for 30 minutes, and centrifugally separated to recover cells. To the recovered cells, 100 ml of ice-cooled sterilized water was added, stirred well, and again centrifu gally separated to recover cells. To the recovered cells, 100 ml of an ice-cooled 10% glycerin solution was added, stirred well, and centrifugally separated to recover cells. The cells were washed again with the ice-cooled 10% glycerin solu tion and suspended in 5 ml of an ice-cold 10% glycerin solution. Then, 400 µl of the resultant cells were mixed with plasmid DNA (pHN144; Nakashima and Tamura; the full length sequence is represented by SEQ ID No: 1) capable of self-replicating in Rhodococcus erythropolis. The mixture solution was transferred to an electroporation cuvette (0.2 cm gap cuvette manufactured by Bio-Rad) and applied with an electric pulse by a gene introduction apparatus, gene pulser II, (manufactured by Bio-Rad) at an electric field of 12.5 kV/cm in strength, a capacitance of 25 uF (the pulse controller), and an external resistance of 400 Ω . The mixture of cells and DNA treated with the electric pulse was mixed with 1 ml of LB medium and cultured at 30° C. for 4 hours.
Thereafter, cells were collected and applied onto LB agar medium containing thiostreptone in a concentration of 10 ug/ml and cultured at 30 $^{\circ}$ C. for 3 days to obtain transformants for each case. The transformation efficiency (the number of colonies formed) per 1 µg of DNA is shown in Table 3.

TABLE 3

Bacterial strain	Deposition No.	Transformation efficiency rate
Rhodococcus erythropolis strain L-65	FERM BP-8443	2.6×10^5
Rhodococcus erythropolis strain L-88	FERM BP-8444	2.5×10^5
Rhodococcus erythropolis strain JCM 3201	ATCC25544	4.0×10^{5}

EXAMPLE 6

[0047] Extraction of recombinant protein produced by Rhodococcus erythropolis strain L-65

[0048] A plasmid (pHN170, Nakashima and Tamura: the full length sequence is represented by SEQ ID No: 2) was constructed such that it could self-replicate in a bacterial cell of Rhodococcus erythropolis and could be induced by thios treptone to express a proline iminopeptidase (hereinafter referred to as "PIP") protein (T. Tamura et al., FEBS Lett. 398, 101-105 (1996)) having a 6x histidine tag at the C terminal. This plasmid was introduced into Rhodococcus erythropolis strain L-65 by an electroporation method. Transformants were screened on LB agar medium contain ing tetracycline (20 μ g/ml). The transformants were inoculated on 4 ml of LB medium containing tetracycline (8 ug/ml) and cultured with shaking at 30° C. until the absor bence at an absorption wavelength of 600 nm reached 0.8. The entire culture solution was added to 40 ml of LB medium containing thiostreptone (1 µg/ml) and cultured with rotation in a vaned flask for 16 hours. After PIP protein was induced to express, bacterial cells were centrifugally collected at 1,500xg for 15 minutes. After the cells thus collected was suspended in 4 ml of a 50 mM phosphate buffer (pH8.0) containing 300 mM salt, lysozyme was added so as to obtain a final concentration of 1 mg/ml. The resultant solution was incubated at 37° C. for one hour, cooled on ice, and centrifuged at 10,000xg for 15 minutes to separate the supernatant (s) and the precipitate (p) . An aliquot of 1 ml was taken from the obtained supernatant (s) and placed in another microcentrifuge tube. To the micro centrifuge tube, 50 ul of Ni-NTA Superflow (manufactured by QIAGEN) was added, which had been previously equili brated with a 50 mM phosphate buffer (pH 8.0) containing 300 mM salt. The resultant mixture was incubated at 4° C. for one hour while turning it upside down, washed three times with 1 ml of a 50 mM phosphate buffer (pH 6.0) containing 300 mM salt and 10% glycerin, and thereafter, eluted with 50 ul of a 50 mM phosphate buffer (pH 6.0) containing 500 mM EDTA, 300 mM salt and 10% glycerin to obtain 6x histidine-fused PIP protein. An aliquot (10 ul) was taken from the protein thus obtained and subjected to SDS polyacrylamide gel electrophoresis. As a result, a clear
band was detected near the molecular weight (34.3 KDa). which was predicted from the amino acid sequence of the $6x$ histidine-fused PIP protein (FIG. 5). On the other hand, the precipitate (p) was resuspended in 1 ml of a 100 mM sodium dihydrogen phosphate -10 mM tris chloride buffer (pH 8.0) containing 8M urea, allowed to stand alone for 30 minutes. and subjected to centrifugation at $10,000 \times g$ for 15 minutes. The resultant supernatant was transferred to a new microcentrifuge tube, 50 ul of Ni-NTA Superflow, which had been previously equilibrated with a 100 mM sodium dihydrogen phosphate -10 mM tris chloride buffer (pH 8.0) containing 8M urea, was added to the microcentrifuge tube, and incu bated at room temperature for one hour while turning upside down. After the microcentrifuge tube was washed three times with 1 ml of a 100 mM sodium dihydrogen phosphate -10 mM tris chloride buffer (pH 6.3) containing 8M urea, it was subjected to elution with 50 ul of a 100 mM sodium dihydrogen phosphate -10 mM tris chloride buffer (pH 8.0) containing 500 mM EDTA and 8M urea to obtain 6x histidine-fused PIP protein. An aliquot $(10 \mu l)$ was taken from the protein thus obtained and subjected to SDS polyacrylamide gel electrophoresis (FIG. 5). Reference symbol

6

M represents a molecular marker and molecular weight is shown at the left side of the figure to indicate an approximate molecular weight of each band. Band patterns of individual lanes are shown in FIG. 5 as follows.

[0049] Lane 1 (JCM 3201,s) shows an electrophoretic pattern of a sample obtained from the supernatant in the case where PIP is expressed by bacterial strain JCM 3201. Since cell lysis rarely takes place in a buffer solution under nondenaturation condition (containing no urea), a desired band (indicated by the arrow) is not detected. Lane 2 (JSM3201, p) shows an electrophoretic pattern of a sample obtained from the precipitate in the case where PIP is expressed by bacterial strain JSM 3201. Lysis takes place slightly in a buffer solution under denaturation conditions (containing urea) and thus a thin band of interest is detected.

 $[0050]$ Lane 3 (JCM3201+amp,s) shows an electrophoretic pattern of a sample obtained from the Supernatant in the case where PIP is expressed by bacterial strain JCM 3201 where the sample is treated with ampicillin for 2 hours before cell collection. Since the sensitivity to lysozyme is increased by the treatment with ampicillin, cell lysis takes place even in nondenaturation conditions. As a result, a desired band can be clearly confirmed.

[0051] Lane 4 (JSM3201+amp, p) shows an electrophoretic pattern of a sample obtained from the precipitate in the case where PIP is expressed by bacterial strain JCM 3201 where the sample is treated with ampicillin for 2 hours before cell collection. It is considered that even though the cells previously treated with ampicillin do not cause cell lysis in a buffer under the nondenaturation conditions, they lyse in a buffer under denaturation conditions to give a detectable desired band.

[0052] Lane 5 (L-65, s) shows an electrophoretic pattern of a sample obtained from the supernatant in the case where PIP is expressed by bacterial strain L-65. Cells were lysed completely with lysozyme treatment to give a detectable desired band.

[0053] Lane 6 (L-65, p) shows an electrophoretic pattern of a sample obtained from the precipitate in the case where PIP is expressed by bacterial strain L-65. Since the precipitate is considered to contains only residual cells after lysis, the desired band is not detected.

[0054] Lane 7 (L-88, s) shows the electrophoretic pattern of a sample obtained from the supernatant in the case where
PIP is expressed by bacterial strain L-88. The same phenomenon as in the case of bacterial stain L-65 is considered.

[0055] Lane 8 (L-88, p) shows the electrophoretic pattern of a sample obtained from the precipitate in the case where PIP is expressed by bacterial strain L-88. The same phenomenon as in the case of stain L-65 is considered.

[0056] As for the antibiotic used in the aforementioned operation, a required amount of a solution containing 5 mg of tetracycline dissolved in 1 ml of 50 wt % ethanol or 10 mg of thiostreptone dissolved in 1 ml of dimethylsulfoxide was used.

EXAMPLE 7

[0057] Extraction of recombinant protein produced by Rhodococcus erythropolis strain L-88

[0058] The same operation as in Example 6 was performed except that Rhodococcus erythropolis strain L-88 was used in place of Rhodococcus erythropolis strain L-65 (FIG. 5).

COMPARATIVE EXAMPLE 2

[0059] Extraction of recombinant protein produced by Rhodococcus erythropolis strain JCM 3201

[0060] The same operation as in Example 6 was performed except that Rhodococcus erythropolis strain JCM 3201 was used in place of Rhodococcus erythropolis strain L-65 (FIG. 5).

COMPARATIVE EXAMPLE 3

[0061] Extraction of recombinant protein produced by Rhodococcus erythropolis strain JCM 3201

0062) A transformant was prepared in the same manner as in Example 6 except that Rhodococcus erythropolis strain
JCM 3201 was used in place of Rhodococcus erythropolis strain L-65. The expression of PIP protein was induced by thiostreptone. Two hours before cell collection, 480 ul of an aqueous solution of ampicillin (50 mg/ml) was added (a final concentration of 600 ug/ml) and subjected to cell collection. Thereafter, the same operations as in Example 6 were performed and the obtained sample was subjected to elec trophoresis (FIG. 5).

[0063] All publications, patents and patent applications cited herein are incorporated herein in its entirety by reference.

INDUSTRIAL APPLICABILITY

[0064] As shown in Examples, a microorganism of the genus *Rhodococcus* of the present invention has an increased sensitivity to lysozyme compared to a wild type strain. The transformation efficiency of the microorganism
of the present invention is not significantly changed from that of the wild-type stain. It is therefore possible to effi ciently transform a microorganism of the genus Rhodococ cus of the present invention by a gene encoding the exog enous protein, express the exogenous protein, cause cell lysis with lysozyme, and extract and recover the protein easily.

Sequence listing free text

[0065] SEQ ID No. 1: Plasmid pHN 144

[0066] SEQ ID No. 2: Plasmid pHN 170

<210> SEQ ID NO 1
<211> LENGTH: 5108 $<$ 212> TYPE: DNA

SEQUENCE LISTING

$-$ continued

$-$ continued

-continued

gttcacgaca ccactgccgt tcaccgaagt acgcgccacc gcgcaatcca tctccaaatg 4440 gatctggcgc aatttcaccg aagaacagta ccgagcccga caagcgcatc tcggtcaaaa 4500 aggcggcaag gcaacgacac tcgccaaaca agaagccgtc cgaaacaatg caagaaagta 4560 4620 cgacgaacat acgatgcgag aggcgattat ctgatgggcg gagccaaaaa tccggtgcgc cgaaagatga cggcagcagc agcagccgaa aaattcggtg cctccactcg cacaatccaa 4680 cgcttgtttg ctgagccgcg tgacgattac ctcggccgtg cgaaagctcg ccgtgacaaa 4740 gctgtcgage tgcggaagca ggggttgaag taccgggaaa tegccgaage gatggaacte 4800 tcgaccggga tcgtcggccg attactgcac gacgcccgca ggcacggcga gatttcagcg 4860 gaggatetgt eggegtaaee aagteagegg gttgtegggt teeggeegge geteggeaet 4920 cggaccggcc ggcggatggt gttctgcctc tggcgcagcg tcagctaccg ccgaaggcct 4980 gtcatcgacc ggcttcgact gaagtatgag caacgtcaca gcctgtgatt ggatgatccg 5040 5100 ctcacgctcg accgctacct gttcagctgc cgcccgctgg gcatgagcaa cggccaactc 5108 tcgttcaa <210> SEQ ID NO 2 <211> LENGTH: 8971 $<$ 212> TYPE: DNA <213> ORGANISM: Artificial Sequence $<$ 220> FEATURE: <223> OTHER INFORMATION: Description of Artificial Sequence: Plasmid pHN170 <400> SEQUENCE: 2 gagetegaee gegegggtee eggaegggga agagegggga getttgeeag agagegaega 60 120 cttccccttg cgttggtgat tgccggtcag ggcagccatc cgccatcgtc gcgtagggtg 180 tcacacccca qqaatcqcqt cactqaacac aqcaqccqqt aqqacqacca tqactqaqtt ggacaccatc gcaaatccgt ccgatcccgc ggtgcagcgg atcatcgatg tcaccaagcc 240 gtcacqatcc aacataaaga caacqttgat cgaggacgtc gagcccctca tgcacagcat 300 360 cgcggccggg gtggagttca tcgaggtcta cggcagcgac agcagtcctt ttccatctga gttgctggat ctgtgcgggc ggcagaacat accggtccgc ctcatcgact cctcgatcgt 420 caaccagttg ttcaaggggg agcggaaggc caagacattc ggcatcgccc gcgtccctcg 480 cccggccagg ttcggcgata tcgcgagccg gcgtggggac gtcgtcgttc tcgacggggt 540 gaagatcgtc gggaacatcg gcgcgatagt acgcacgtcg ctcgcgctcg gagcgtcggg 600 gatcatcctg gtggacagtg acatcaccag catcgcggac cggcgtctcc aaagggccag 660 ccgaggttac gtcttctccc ttcccgtcgt tctctccggt cgcgaggagg ccatcgcctt 720 780 cattcgggac agcggtatgc agctgatgac gctcaaggcg gatggcgaca tttccgtgaa 840 ggaactcggg gacaatccgg atcggctggc cttgctgttc ggcagcgaaa agggtgggcc 900 ttccgacctg ttcgaggagg cgtcttccgc ctcggtttcc atccccatga tgagccagac 960 cgagtctctc aacgtttccg tttccctcgg aatcgcgctg cacgagagga tcgacaggaa tetegeggee aaeegataag egeetetgtt eeteggaege teggtteete gaeetegatt 1020 cgtcagtgat gatcacctca cacggcagcg atcaccactg acatatcgag gtcaacggtc 1080 1140

gtggtccggg cgggcactcc tcgaaggcgc ggccgacgcc cttgaacgac tcgatgactc

 $\mathbf Q$

 $\frac{1}{2}$

 $\overline{11}$

ntinuad

1. A mutant of a microorganism of the genus Rhodococcus having a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus.

2. The microorganism of the genus Rhodococcus according to claim 1, wherein the microorganism of the genus Rhodococcus is Rhodococcus erythropolis.

3. The microorganism of the genus Rhodococcus accord ing to claim 2, wherein the Rhodococcus erythropolis is Rhodococcus erythropolis strain L-65 (Accession No. FERM BP-8443) or Rhodococcus erythropolis strain L-88 (Accession No. FERM BP-8444).

4. A method of producing a protein comprising transform ing a mutant of a microorganism of the genus Rhodococcus having a higher sensitivity to lysozyme than a wild-type microorganism of the genus Rhodococcus by a gene encod ing an exogenous protein; expressing the gene; and treating the microorganism of the genus Rhodococcus with lysozyme, thereby extracting and recovering the protein.

5. The method of producing a protein according to claim 4, wherein the microorganism of the genus Rhodococcus is Rhodococcus erythropolis.

6. The method of producing a protein according to claim 5, wherein the Rhodococcus erythropolis is Rhodococcus erythropolis strain L-65 (Accession No. FERM BP-8443) or Rhodococcus erythropolis strain L-88 (Accession No. FERM BP-8444).

> $* * * *$ \star